What is Avalo Therapeutics's total equity?

Avalo Therapeutics (AVTX) reported total equity of $68.32M in Q1 2026.

How has Avalo Therapeutics's total equity changed year-over-year?

Avalo Therapeutics's total equity decreased by 44.3% year-over-year, from $122.62M to $68.32M.

What is the long-term trend for Avalo Therapeutics's total equity?

Over 5 years (2020 to 2025), Avalo Therapeutics's total equity has grown at a 27.6% compound annual growth rate (CAGR), from $24.56M to $83.05M.

What does total equity mean?

Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Avalo Therapeutics AVTX Total Equity

Total Equity at other companies

Eli LillyLLY

$31.2B+97.9%

AbbVieABBV

-$6.66B-569%

XencorXNCR

$515.63M-19.4%

AbCellera Biologics Inc.ABCL

$938.08M-8.3%

AnaptysBio, Inc.ANAB

$12.75M-62.5%

Absci CorporationABSI

$171.97M-13.5%

Other financials

Income statement

See full

Revenue$59.0K-69.3%

Gross profit$963.0K+8,855%

Operating income-$20.9M-42.5%

Net income-$19.6M-49.3%

EPS (diluted)-$0.98+21.6%

Balance sheet

See full

Cash & equivalents$25.3M-79.8%

Total debt$328.0K-59.1%

Total assets$99.9M-27.9%

Cash flow

See full

Operating cash flow-$17.7M-87.1%

CapEx-—

Free cash flow-$15.0M-444%

Valuation

See full

Market cap$954.59M+1,800%

Enterprise value$929.6M-1,353%

P/S1,909.2×+1,868×

Profitability

See full

Gross margin182%+176pp

Operating margin-15,536.1%-17,275pp

Net margin-7,965.8%-10,750pp

FCF margin-11,123.8%-13,374pp

Returns & leverage

See full

Return on equity-88.8%—

Debt / equity0×0.0×

Current ratio7.7×-14.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avalo Therapeutics's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Avalo Therapeutics's total equity?: Avalo Therapeutics (AVTX) reported total equity of $68.32M in Q1 2026.
How has Avalo Therapeutics's total equity changed year-over-year?: Avalo Therapeutics's total equity decreased by 44.3% year-over-year, from $122.62M to $68.32M.
What is the long-term trend for Avalo Therapeutics's total equity?: Over 5 years (2020 to 2025), Avalo Therapeutics's total equity has grown at a 27.6% compound annual growth rate (CAGR), from $24.56M to $83.05M.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.